28 May 2025
EMA/175872/2025
Press office

Recommendations on eligibility to PRIME scheme

Adopted at the CHMP meeting of 19-22 May 2025

During its May 2025 meeting, the CHMP reviewed 4 recommendations for eligibility to PRIME: 1 was granted and 3 were denied. The individual outcomes adopted this month are listed below.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

Eligibility granted

Name*	Product type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
ChAdOx1 NipahB	Biological Medicinal Product	Infections and infestations	Prevention of Nipah virus infection	Non-clinical + clinical exploratory	Academia

* Name of the active substance, INN, common name, chemical name or company code.

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other types of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.

Eligibility denied

Product type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
Advanced Therapy Medicinal Product	Congenital, familial and genetic disorders	Treatment of Pompe disease	Non-clinical + clinical exploratory	Other
Advanced Therapy Medicinal Product	Musculoskeletal and connective tissue disorders	Treatment of osteoarthritis of the knee and hip	Non-clinical + clinical exploratory	SME
Advanced Therapy Medicinal Product	Congenital, familial and genetic disorders	Treatment of inherited retinal dystrophies due to dysfunction in the ABCA4 gene	Non-clinical + clinical exploratory	SME

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other type of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.

Cumulative overview of PRIME eligibility recommendations adopted by 22 May 2025

Granted Denied Out of scope* Withdrawn

Overall number



By Applicant Type



By therapeutic area



* This indicates eligibility requests received but not started by EMA as they were deemed outside the scope of the scheme or with a format and content inadequate to support their review. These are not included in the breakdown by type of applicant or by therapeutic area.